1. A gene expression study denies the ability of 25 candidate biomarkers to predict the interferon-beta treatment response in multiple sclerosis patients
- Author
-
Serena Martire, Nicole Desiree Navone, Antonio Bertolotto, Simona Perga, and Francesca Montarolo
- Subjects
Adult ,Male ,0301 basic medicine ,Oncology ,medicine.medical_specialty ,Multiple Sclerosis ,Adolescent ,Immunology ,Gene Expression ,Biology ,TRIM22 ,Statistics, Nonparametric ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Immunology and Allergy ,CXCL10 ,RNA, Messenger ,Young adult ,Retrospective Studies ,Whole blood ,Multiple sclerosis ,Retrospective cohort study ,Interferon-beta ,Middle Aged ,medicine.disease ,Interleukin 10 ,030104 developmental biology ,Neurology ,Cytokines ,IRF7 ,Female ,Neurology (clinical) ,Biomarkers ,030217 neurology & neurosurgery - Abstract
We studied the baseline expression level of 25 interferon-regulated genes (MxA, GPR3, IL17RC, ISG15, TRAIL, OASL, IFIT1, IFIT2, RSAD2, OAS3, IFI44L, TRIM22, IL10, CXCL10, STAT1, OAS1, OAS2, IFNAR1, IFNAR2, IFNβ, ISG20, IFI6, PKR, IRF7, USP18), recurrently proposed in the literature as predictive biomarkers of interferon-beta treatment response, in whole blood of 10 "responders" and 10 "non-responders" multiple sclerosis relapsing-remitting patients, retrospectively selected on the basis of stringent clinical criteria after a five years follow-up. However, we cannot confirm the predictive value of these candidate biomarkers.
- Published
- 2016